Hokkaido University Collection of Scholarly and Academic Papers >
Institute for Genetic Medicine >
Peer-reviewed Journal Articles, etc >
Oral administration of the β-glucan produced by Aureobasidium pullulans ameliorates development of atherosclerosis in apolipoprotein E deficient mice
This item is licensed under:Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Title: | Oral administration of the β-glucan produced by Aureobasidium pullulans ameliorates development of atherosclerosis in apolipoprotein E deficient mice |
Authors: | Aoki, Shiho Browse this author | Iwai, Atsushi Browse this author | Kawata, Koji Browse this author | Muramatsu, Daisuke Browse this author | Uchiyama, Hirofumi Browse this author | Okabe, Mitsuyasu Browse this author | Ikesue, Masahiro Browse this author | Maeda, Naoyoshi Browse this author | Uede, Toshimitsu Browse this author →KAKEN DB |
Keywords: | β-glucan | Aureobasidium pullulans | Atherosclerosis |
Issue Date: | Oct-2015 |
Publisher: | Elsevier |
Journal Title: | Journal of Functional Foods |
Volume: | 18 |
Start Page: | 22 |
End Page: | 27 |
Publisher DOI: | 10.1016/j.jff.2015.06.044 |
Abstract: | The Aureobasidium pullulans-produced β-glucan (AP-PG) is an immune stimulator, and believed to exhibit beneficial effects on health through its immune stimulating activity. Here, the effect of oral administration of AP-PG on high-fat diet (HFD)-induced atherosclerosis was evaluated using apolipoprotein E deficient mice, a widely used mouse model for atherosclerosis. The results demonstrated that HFD-induced development of atherosclerosis was significantly reduced in the AP-PG-treated mice when compared with that of the control mice. In serological analysis, blood levels of oxidized low-density lipoprotein cholesterol, a well-known risk factor for the development of atherosclerosis, were significantly reduced in the AP-PG-treated group of mice. Further, immunohistochemical analysis using MOMA-2 antibody showed that oral administration of AP-PG is effective in ameliorating vascular accumulation of macrophages. These data suggest the possibility that oral administration of AP-PG is effective in ameliorating HFD-induced development of atherosclerosis. |
Rights: | © 2015. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/63473 |
Appears in Collections: | 遺伝子病制御研究所 (Institute for Genetic Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 岩井 淳
|